@article{amrane:hal-04143393,
TITLE = {First-line pembrolizumab for non--small cell lung cancer patients with PD-L1~$\ge$50\% in a multicenter real-life cohort: The PEMBREIZH study},
AUTHOR = {Amrane, Karim and Geier, Margaux and Corre, Romain and L{\'e}na, Herv{\'e} and L{\'e}veiller, Guillaume and Gadby, Florence and Lamy, R{\'e}gine and Bizec, Jean-louis and Goarant, Eric and Robinet, Gilles and Gouva, Sylvie and Quere, Gilles and Abgral, Ronan and Schick, Ulrike and Bernier, Cyril and Chouaid, Christos and Descourt, Renaud},
URL = {https://hal.u-pec.fr/hal-04143393},
JOURNAL = {Cancer Medicine},
PUBLISHER = {Wiley},
VOLUME = {9},
NUMBER = {7},
PAGES = {2309-2316},
YEAR = {2020},
MONTH = Apr, DOI = {10.1002/cam4.2806},
KEYWORDS = {first-line monotherapy ; non-small cell lung cancer ; PD-L1 tumor proportion score ; pembrolizumab ; Real world},
PDF = {https://hal.u-pec.fr/hal-04143393/file/CAM4-9-2309.pdf},
HAL_ID = {hal-04143393},
HAL_VERSION = {v1},
}